In a move to bolster its offerings of rare disease treatments, Johnson & Johnson announced on Jan. 26 the largest deal in its history with a proposed $30 billion buy of Swiss biotechnology company Actelion Ltd.
The all-cash deal gives the world’s largest health care company access to Actelion’s lucrative medications for high blood pressure, pulmonary arterial hypertension and other rare conditions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
